Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Oral Fecal Microbiota Transplant Feasibility Study in Alzheimer's Disease (AMBITION)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03998423
Recruitment Status : Recruiting
First Posted : June 26, 2019
Last Update Posted : October 8, 2019
Sponsor:
Collaborator:
Wisconsin Partnership Program
Information provided by (Responsible Party):
University of Wisconsin, Madison

Brief Summary:
The goal of this study is to assess the safety and feasibility of an oral fecal microbiota transplant (FMT) intervention for Alzheimer's disease (AD).

Condition or disease Intervention/treatment Phase
Alzheimer Disease Biological: Fecal Microbiota Transplant Phase 1

Detailed Description:

Studies suggests that microbes, including those derived from the gut, may play a role in the development or progression of AD. Gut microbiome composition among individuals with the Alzheimer's clinical syndrome is reduced in microbial diversity and shows compositional differences relative to control groups. Further, genera identified as more abundant in AD are associated with greater AD pathology while genera identified as less abundant in AD are associated with less AD pathology, as shown using CSF biomarkers.

The goal of this study is to assess the safety and feasibility of an oral fecal microbiota transplant (FMT) intervention.

  • Primary Objective: To assess the safety and feasibility (recruitment, eligibility, enrollment, completion, and follow-up) of an oral FMT intervention in people with and without the Alzheimer's clinical syndrome.
  • Secondary Objective: To demonstrate the effects of FMT on the composition and function of the gut microbiota. To collect preliminary data in order to estimate sample size and other parameters for a larger study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: A single dose of 30 capsules (22.5g) of oral FMT will be given once (week 0), twice (week 0 and week 8), or three times (week 0, week 8, and week 24). Participants are randomly assigned to 1, 2, or 3 doses of FMT.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Oral Fecal Microbiota Transplant Feasibility Study in Alzheimer's Disease
Estimated Study Start Date : October 2019
Estimated Primary Completion Date : May 31, 2022
Estimated Study Completion Date : May 31, 2022


Arm Intervention/treatment
Experimental: 1 dose fecal microbiota transplant
This group will receive one dose of Fecal Microbiota Transplant (FMT) at baseline.
Biological: Fecal Microbiota Transplant
Double-encapsulated Fecal Microbiota Transplant Capsules
Other Name: FMT Capsule DE

Experimental: 2 doses fecal microbiota transplant
This group will will receive one dose of Fecal Microbiota Transplant (FMT) at baseline and a second dose of FMT 8 weeks later.
Biological: Fecal Microbiota Transplant
Double-encapsulated Fecal Microbiota Transplant Capsules
Other Name: FMT Capsule DE

Experimental: 3 doses fecal microbiota transplant
This group will will receive one dose of Fecal Microbiota Transplant (FMT) at baseline, second dose of FMT at 8 weeks, and a third dose of FMT at 12 weeks.
Biological: Fecal Microbiota Transplant
Double-encapsulated Fecal Microbiota Transplant Capsules
Other Name: FMT Capsule DE




Primary Outcome Measures :
  1. Safety: Proportion of participants with treatment-related adverse events, serious adverse events, or adverse events of special interest. [ Time Frame: 1 year ]

    Proportion of participants with treatment-related adverse events, serious adverse events, or adverse events of special interest.

    Adverse events, serious adverse events, or adverse events of special interest, will be evaluated following study procedures using AE and SAE forms, telephone and in person interview, and relevant medical records related to adverse events.


  2. Feasibility: Participant recruitment rate [ Time Frame: 1 year ]
    Number of weeks/months needed to meet study group numbers.

  3. Feasibility: Eligibility [ Time Frame: 1 year ]
    Proportion of individuals expressing interest who meet inclusion/exclusion criteria.

  4. Feasibility: Procedures completed. [ Time Frame: 1 year ]
    Proportion of participants able to complete procedures (including FMT) will be part of feasibility.

  5. Feasibility: Retention [ Time Frame: 1 year ]
    Proportion of participants that complete follow up.

  6. Change in gut composition: Engraftment of fecal microbial transplant as assessed by 16S rRNA sequencing of recipient stool sample [ Time Frame: baseline, 8 weeks, 24 weeks, 1 year ]
    In order to determine efficacy of fecal transplant, change in composition, i.e. microbial engraftment will be assessed by testing for newly detected operational taxonomic units (OTUs) in the gut microbiome of a participant post-FMT (which were present in the donor but undetected in the participant pre-FMT). This will be assessed via 16S rRNA seq of recipient stool samples pre- and post- FMT.


Secondary Outcome Measures :
  1. Cognition: Change in Montreal Cognitive Assessment (MoCA) score [ Time Frame: baseline and 1 year ]
    The Montreal Cognitive Assessment (MoCA) is a cognitive screening test used for detecting cognitive impairment. MoCA scores range between 0 and 30. Lower scores are indicative of impairment

  2. Cognition: Change in results of Repeatable Battery for the Assessment of Neuropsychological Status [ Time Frame: baseline and 1 year ]
    The Repeatable Battery for the Assessment of Neuropsychological Status consists of twelve subtests which give five scores, one for each of the five domains tested (immediate memory, visuospatial/constructional, language, attention, delayed memory). Raw scores on each domain are scaled to account for a person's age. Scaled scores are converted to percentiles which are used to determine a range of performance (impaired, borderline impaired, expected score, high average, superior) and overall cognitive status (impaired/not impaired).

  3. Cognition: Change in the results of Trail Making Test Part A and Part B [ Time Frame: baseline and 1 year ]

    The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts, A and B. Participant is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy. The test can provide information about visual search speed, scanning, speed of processing, mental flexibility, as well as executive functioning.

    Results for both TMT A and B are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment.


  4. Metabolic/physiological measure: Change in the level of Hemoglobin A1C [ Time Frame: baseline, 8 weeks, 24 weeks, and 1 year ]
    Change in the level of Hemoglobin A1C will be assessed

  5. Metabolic/physiological measure: Change in the level of fasting glucose [ Time Frame: baseline, 8 weeks, 24 weeks, and 1 year ]
    Change in the level of fasting glucose will be assessed

  6. Metabolic/physiological measure: Change in the level of fasting insulin [ Time Frame: baseline, 8 weeks, 24 weeks, and 1 year ]
    Change in the level of fasting insulin will be assessed

  7. Metabolic/physiological measure: Change in the level of C-reactive protein [ Time Frame: baseline, 8 weeks, 24 weeks, and 1 year ]
    Change in the level of C-reactive protein will be assessed

  8. Metabolic/physiological measure: Change in the blood lipid profile [ Time Frame: baseline, 8 weeks, 24 weeks, and 1 year ]
    Change in the blood lipid profile will be assessed

  9. Metabolic/physiological measure: Change in the blood pressure [ Time Frame: baseline, 8 weeks, 24 weeks, and 1 year ]
    Change in the blood pressure will be assessed

  10. Metabolic/physiological measure: Change in body weight [ Time Frame: baseline, 8 weeks, 24 weeks, and 1 year ]
    Change in body weight will be assessed

  11. Metabolic/physiological measure: Change in the body composition by measuring body fat percentage [ Time Frame: baseline and 1 year ]
    Change in the body composition by measuring body fat percentage

  12. Change in insulin resistance indexed by the homeostatic model assessment-insulin resistance (HOMA-IR) method [ Time Frame: baseline, 8 weeks, 24 weeks, and 1 year ]
    Fasting glucose and fasting insulin will be used to calculate HOMA-IR.

  13. Change in physical activity as measured by Actigraphy watch [ Time Frame: baseline, 24 weeks, and 1 year ]
    Actigraphy watch will be worn on the non-dominant wrist was used to record a participant's physical activity (total number of active minutes per day).

  14. Change in Sleep as measured by Actigraphy watch [ Time Frame: baseline, 24 weeks, and 1 year ]
    Actigraphy watch will be worn on the non-dominant wrist to estimate sleep duration.

  15. Change in CSF biomarkers [ Time Frame: baseline and 1 year ]
    Aβ42, Aβ42/Aβ40, phosphorylated tau, total tau, YKL-40

  16. Change in serum/plasma metabolites on an average of one week pre and post FMT [ Time Frame: baseline, week 8, week 24, and 1 year ]
    Change in serum/plasma metabolites on an average of one week pre and post FMT

  17. Function: Change in total score on the Bristol Activities of Daily Living Scale [ Time Frame: baseline and 1 year ]
    Change in total score on the Bristol Activities of Daily Living Scale. This is a tool used to measure functional ability (ability to independently carry out activities of daily living), and was developed for use with people with dementia. The minimum score is "0". The maximum score is "60". A lower score (better) indicates that a person is independent in their activities of daily living, and a higher score (worse) indicates that the individual is dependent on others.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Current enrollment in the Wisconsin ADRC clinical core study (2011-0030), ADCP (26695, MCW IRB), or referred from clinic
  • At least 45 years of age
  • Good general health (other than dementia) with no conditions/medications affecting the gut microbiome (see exclusion criteria below)
  • Willing and able to comply with all study procedures for the duration of the study
  • Able to provide signed and date informed consent form
  • Participant is not pregnant, lactating or of childbearing potential (ie women must be two years post-menopausal or surgically sterile
  • Males must agree to avoid impregnation of women during and for four weeks after completing study treatment through use of an acceptable method of contraception
  • Able to take oral medications
  • Able to take the test capsule successfully with no signs or symptoms of dysphagia

Additional inclusion criteria for participants with Alzheimer's disease:

  • Abnormal memory function documented by neuropsychological testing
  • Wisconsin ADRC (HS IRB# 2015-0030) Consensus Diagnosis Conference indicates probable AD diagnosis as per NINDS/ADRDA criteria for probable AD (for ADRC and ADCP participants only).

Exclusion Criteria:

  • Active or previous (within 6 months) participation in an Alzheimer's clinical intervention/trial
  • Significant neurologic disease: Any significant neurologic disease, such as Parkinson's disease, stroke, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, subdural hematoma, multiple sclerosis, seizure disorder, or other significant deficits (other than Alzheimer's dementia)
  • Alcohol/substance: history of alcohol/substance dependence since joining the cohort
  • Psychiatric disorders: Untreated current axis 1 DSM-V disorder such as major untreated depression, current untreated bipolar 1 disorder, untreated schizophrenia spectrum disorders, or other conditions potentially affecting study adherence.
  • Significant medical illness: any significant systemic illness or unstable medical condition occurring that could affect cognition (other than Alzheimer's). Examples include malignant cancer, chemotherapy, untreated thyroid disease, heart failure, or renal insufficiency.
  • Illiterate, blind, or non-English speaking
  • Known periodic antibiotic use (i.e. prior to dental appointments)
  • Oral FMT-specific exclusion criteria:

    • Inability (e.g. dysphagia) or unwilling to swallow capsules - assessed using the Eating Assessment Tool (EAT-10) and bedside 3oz water swallow test administered by CRU nurse or study coordinator
    • Active gastrointestinal infection at time of enrollment
    • Known or suspected toxic megacolon and/or known small bowel ileus
    • History of total colectomy or bariatric surgery
    • Concurrent intensive induction chemotherapy, radiation therapy, or biological treatment for active malignancy
    • Unable or unwilling to comply with protocol requirements
    • Expected life expectancy < 6 months
    • Previous FMT or microbiome-based products at any time excluding this study
    • Patients with severe anaphylactic or anaphylactoid food allergy
    • Solid organ transplant recipients ≤ 90 days post-transplant or on active treatment for rejection
    • Immunocompromised/ at risk of CMV/EBV associated disease
    • A condition that would jeopardize the safety or rights of the subject, would make it unlikely for the subject to complete the study, or would confound the results of the study
  • Exclusionary factors affecting the microbiome:

    • Use of systemic antibiotics (intravenous, intramuscular, or oral) in the previous 3 months
    • Oral, intravenous, intramuscular, nasal or inhaled corticosteroids (except PRN use for allergies)
    • Immune stimulating medications
    • Methotrexate or immunosuppressive cytotoxic agents
    • Large doses of commercial probiotics consumed (greater than or equal to 108 cfu or organisms per day). Includes tablets, capsules, lozenges, chewing gum or powders in which probiotic is a primary component (ordinary dietary components such as fermented beverages/milks, yogurts, foods do not apply).
    • Unstable dietary history during the previous month, which is defined as major changes in diet by eliminating or significantly increasing a major good group
    • Major surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years
    • Major bowel resection at any time
    • Active uncontrolled gastrointestinal disorders or disease including: inflammatory bowel disease including ulcerative colitis (mild-moderate-severe), Crohn's disease (mild-moderate-severe), or indeterminate colitis; irritable bowel syndrome (moderate-severe); persistent, infectious gastroenteritis, colitis or gastritis; persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent) or Helicobacter pylori infection (untreated), or chronic constipation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03998423


Contacts
Layout table for location contacts
Contact: Barbara Bendlin, PhD (608) 265-2483 bbb@medicine.wisc.edu
Contact: Sandy Harding, MS (608) 262-4760 sjharding@wisc.edu

Locations
Layout table for location information
United States, Wisconsin
University of Wisconsin - Madison Recruiting
Madison, Wisconsin, United States, 53792
Contact: Sandy Harding, MS    608-262-4760    sjharding@wisc.edu   
Principal Investigator: Barbara Bendlin, PhD         
Sub-Investigator: Federico Rey, PhD         
Sub-Investigator: Nathaniel Chin, MD         
Sponsors and Collaborators
University of Wisconsin, Madison
Wisconsin Partnership Program
Investigators
Layout table for investigator information
Principal Investigator: Barbara Bendlin, PhD University of Wisconsin, Madison

Publications:
Layout table for additonal information
Responsible Party: University of Wisconsin, Madison
ClinicalTrials.gov Identifier: NCT03998423     History of Changes
Other Study ID Numbers: AMBITION
2018-0283 ( Other Identifier: UW IRB )
First Posted: June 26, 2019    Key Record Dates
Last Update Posted: October 8, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders